Ahn Soo Kyung, Hwang Ji Woong
Department of Surgery, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul 07441, Republic of Korea.
J Oncol. 2020 Nov 5;2020:4708394. doi: 10.1155/2020/4708394. eCollection 2020.
In recent years, many studies have focused on the host immune system and its relationship with tumor progression in a variety of solid tumors, including breast cancer. This study investigates recent trends of immunotherapy research in breast cancer and compares the contributions of research from different regions, institutions, and authors. A search of breast cancer and immunotherapy studies that were published between 2010 and 2019-with different keyword combinations-was performed in the Web of Science database. Bibliometric data were collected for analysis. VOSviewer software was used to generate a figure for the keyword's co-occurrence network, so as to implement network visualization analysis. A total of 1,041 publications were identified. The United States and China contributed to approximately 50% of the publications, 336 and 208, respectively. Both countries drove the increase in publications after 2015. A paper entitled "Pembrolizumab in patients with advanced triple-negative breast cancer: Phase IB KEYNOTE-012 Study" that was published in the by Nanda et al. was the most cited (715 citations). The keywords found in this research were grouped into four clusters: "mechanism," "vaccination," "PD-L1," and "chemotherapy." The terms "tumor-infiltrating lymphocytes" and "PD-1/PD-L1" are among the latest hotspots, which mostly appeared in 2017. Author keyword analysis revealed that recent trends in breast cancer immunotherapy focus on the triple-negative breast cancer subtype and PD-1/PD-L1 immune checkpoint pathway and inhibitors. This study analyzed global trends in immunotherapy research on breast cancer over the past 10 years and provided insight into the features and research hotspots of the articles in this issue.
近年来，许多研究聚焦于宿主免疫系统及其在包括乳腺癌在内的多种实体瘤中与肿瘤进展的关系。本研究调查了乳腺癌免疫治疗研究的近期趋势，并比较了不同地区、机构和作者的研究贡献。在Web of Science数据库中，使用不同的关键词组合搜索了2010年至2019年间发表的乳腺癌和免疫治疗研究。收集文献计量数据进行分析。使用VOSviewer软件生成关键词共现网络的图，以进行网络可视化分析。共识别出1041篇出版物。美国和中国分别贡献了约50%的出版物，即336篇和208篇。两国在2015年后推动了出版物数量的增加。Nanda等人发表在《 》上的一篇题为《帕博利珠单抗治疗晚期三阴性乳腺癌：1B期KEYNOTE-012研究》的论文被引用次数最多（715次）。本研究中发现的关键词分为四个簇：“机制”“疫苗接种”“PD-L1”和“化疗”。“肿瘤浸润淋巴细胞”和“PD-1/PD-L1”等术语是最新的热点，大多出现在2017年。作者关键词分析表明，乳腺癌免疫治疗的近期趋势集中在三阴性乳腺癌亚型以及PD-1/PD-L1免疫检查点途径和抑制剂上。本研究分析了过去10年乳腺癌免疫治疗研究的全球趋势，并深入了解了该领域文章的特点和研究热点。
